Literature DB >> 19690830

Copper chelation as a potential treatment for left-ventricular hypertrophy in type 2 diabetes.

S J L Bakker, G Navis, R O B Gans.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690830      PMCID: PMC2744789          DOI: 10.1007/s00125-009-1495-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


× No keyword cloud information.
To the Editor: We read with great interest the report by Cooper et al. [1] on unblinded treatment for left-ventricular hypertrophy in type 2 diabetes patients using triethylenetetramine for chelation of copper vs placebo. The results are very promising and certainly merit independent confirmation in larger double-blind, placebo-controlled trials. The authors should be commended for their detailed description of measurement of the primary endpoint of their study, left-ventricular mass by magnetic resonance imaging. However, the authors did not provide information on the way they measured serum copper or urinary copper excretion. Such information would be of interest for future trials and comparison of obtained results. It would also be of interest if the authors could discuss the seeming discrepancy between their conclusion that copper excretion fell to placebo levels after 12 months of treatment, while mean values shown in Fig. 2b of their article seem to plateau at approximately 6 times those of placebo after 10 and 12 months of treatment, with the difference at 10 months of treatment still highly significant. It seems that the non-significance of the p value at 12 months of treatment could be the consequence of loss of statistical power for comparison rather than of a decline in copper excretion between 10 and 12 months of treatment. In their report, the authors state that during the last 6 months of the study, five patients discontinued triethylenetetramine and one patient discontinued placebo. To effectively judge statistical power at 10 vs 12 months of treatment, it would be important to know how many patients discontinued during the last 2 months of the study. This is important because the authors suggested that triethylenetetramine only leads to excretion of ‘excess’ copper, without threat of deficiency [1], while ongoing copper loss could lead to copper deficiency with risk of anaemia, pancytopenia and neurodegeneration [2, 3]. Another relevant point concerning the statistical analyses is that the copper values appeared to be highly skewed, in which case it would be more appropriate to report transformed values and use non-parametric statistics.
  3 in total

Review 1.  Copper deficiency and neurological disorders in man and animals.

Authors:  Paolo Zatta; Adrian Frank
Journal:  Brain Res Rev       Date:  2007-01-31

2.  A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.

Authors:  G J S Cooper; A A Young; G D Gamble; C J Occleshaw; A M Dissanayake; B R Cowan; D H Brunton; J R Baker; A R J Phillips; C M Frampton; S D Poppitt; R N Doughty
Journal:  Diabetologia       Date:  2009-01-27       Impact factor: 10.122

Review 3.  Hematological manifestations of copper deficiency: a retrospective review.

Authors:  Thorvardur R Halfdanarson; Neeraj Kumar; Chin-Yang Li; Robert L Phyliky; William J Hogan
Journal:  Eur J Haematol       Date:  2008-02-12       Impact factor: 2.997

  3 in total
  1 in total

1.  Analysis of serum and urinal copper and zinc in Chinese northeast population with the prediabetes or diabetes with and without complications.

Authors:  Jiancheng Xu; Qi Zhou; Gilbert Liu; Yi Tan; Lu Cai
Journal:  Oxid Med Cell Longev       Date:  2013-09-22       Impact factor: 6.543

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.